In a Canadian T2D model, dulaglutide increased projected quality-adjusted life expectancy versus insulin glargine.
In plain wordsComputer projections for Canadian T2D predicted longer quality-adjusted life with dulaglutide than insulin glargine.
- Peptide
- Dulaglutide (Trulicity)
- Outcome
- IncreaseProjected quality-adjusted life expectancy
- Study
n: not reported in source
Patient-level cost-utility model of Type 2 diabetes- Comparator
- Insulin glargine
- Outcome group
- Quality of life · Whole body
Measurements
- QALE gain
- 0.38 QALYs
- dulaglutide 1.5 mg versus insulin glargine
Source sentences
Based on the AWARD-2 trial, relative to insulin glargine, dulaglutide 1.5 mg was projected to increase QALE by 0.38 quality-adjusted life years and increase costs by CAD 19,773, resulting in an incremental cost-effectiveness ratio of CAD 52,580 per quality-adjusted life year gained.
4 context sentences(design, population, supporting numbers)
In the present analysis, we evaluated the cost-effectiveness of dulaglutide 1.5 mg, a once-weekly glucagon-like peptide 1 agonist as third-line therapy relative to insulin glargine from the perspective of a Canadian healthcare payer.
A patient-level cost-utility model of Type 2 diabetes was developed to capture seven microvascular and macrovascular complications and severe and nonsevere hypoglycemia.
Cohort characteristics and the relative efficacy of dulaglutide 1.5 mg and insulin glargine were derived from the AWARD-2 head-to-head trial, which was identified by systematic literature review.
Cost data were derived from Canadian sources and expressed in 2016 Canadian dollars (CAD), and future cost and quality-adjusted life expectancy (QALE) estimates were discounted at 1.5% per annum.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).